menu

Chronic Pulmonary Aspergillosis Drugs Market

Schedule Call

Chronic Pulmonary Aspergillosis Drugs Market

Chronic Pulmonary Aspergillosis Drugs Market by Drug Class (Azole Antifungals, Antibiotics, and Others), by Route of Administration (Oral, and Parenteral) - Global Outlook & Forecast 2022-2030

GR - 634460 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: December 06, 2022

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Chronic Pulmonary Aspergillosis Drugs Market Scope

Report Attribute

Details

Market size value in 2021

US$ 3.9 Billion

Revenue forecast in 2030

US$ 5.94 billion

Growth Rate

CAGR of 4.8% from 2022 to 2030

Base year for estimation

2021

Forecast period

2022-2030

Segments covered

Drug, Distribution Channel, and Region

Regional scope

North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Report Overview

The global chronic pulmonary aspergillosis drugs market was pegged at US$ 3.9 billion in 2021 and is expected to witness a CAGR of 4.8% during the forecast period.

Market Fundamentals

A single or many cavities, nodules, infiltrates, or fibrosis, with or without an aspergilloma, are some of the lung parenchymal damage signs of chronic pulmonary aspergillosis (CPA). Treating is not always simple given the frequently various co-morbidities associated with CPA, the complex clinical picture, the pharmacological interactions, toxicities, and intolerances. Itraconazole or voriconazole taken orally is the first line of defense. Itraconazole and voriconazole may be switched for patients in the event of intolerance or toxicity. Posaconazole third-line therapy may be started in the event of resistance or increased intolerance. Fourth-line treatments include brief rounds of intravenous liposomal amphotericin B or micafungin in patients who have developed pan-azole resistance, keeping in mind the nephrotoxic nature of amphotericin B.

[864533]

Market Dynamic

There is a lot of research and development going on in the market for CPA medications, and many new products are being introduced. As a result, manufacturers are compelled to meet the growing patient demand for effective and efficient treatment modalities. Most businesses make significant research investments in the creation of novel drug regimens and provide significant financial assistance. This has assisted in the global market's expansion. Therefore, there would be a sizable market potential due to the high unmet need for curative aspergillosis treatment. Emerging economies in Asia, where the disease prevalence is quite high, are projected to be the main drivers of growth in the global market for medications treating chronic pulmonary aspergillosis.

Market Ecosystem

The global chronic pulmonary aspergillosis drugs market has been analyzed from three perspectives, drug, distribution channel, and region.

Chronic pulmonary aspergillosis drugs Market by Drug Class

[324234325]

Based on drug type, the global chronic pulmonary aspergillosis drugs market has been subdivided into, azole antifungals, antibiotics, and others. The mainstay of oral therapy for chronic pulmonary aspergillosis is triazole medication, which is now regarded as the standard of care. The first-line treatment is itraconazole, which has an overall response rate of 76.5%, The liposomal amphotericin B is utilized in CPA in cases of azole intolerance, failure of azole therapy, or fast-progressing disease. Since azole antifungals are the first line of treatment in this disease, it is thus dominating the global market.

Chronic pulmonary aspergillosis drugs Market by Route of Administration

Based on end-user, the global chronic pulmonary aspergillosis drugs market has been divided into, oral and parenteral. Due to greater absorption and effectiveness, oral itraconazole and voriconazole are the main therapy options for chronic pulmonary aspergillosis. Life-threatening hemoptysis may be prevented or treated with oral itraconazole medication. Thus oral segment dominates the global chronic pulmonary aspergillosis drugs market.

Chronic pulmonary aspergillosis drugs Market by Region 

Based on region, the global chronic pulmonary aspergillosis drugs market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe is the region with a major prevalence of chronic pulmonary aspergillosis cases.  The prevalence of tuberculosis is also one of the reasons for the increase in CPA cases. The presence of key players participating in developing new drugs for the treatment of CPA is also driving the European market. To develop and market olorofim, an antifungal medication for invasive fungal infections, in Europe and Asia, the UK company F2G Ltd. has established a strategic partnership with the Japanese pharmaceutical company Shionogi & Co. Ltd.

Competitive Landscape

Some of the prominent players operating in the global chronic pulmonary aspergillosis drugs market are: - 

  • Pfizer Inc.
  • Merck & Co.
  • Astellas Pharma
  • Gilead Science Inc.
  • Novartis AG
  • Johnson & Johnson 
  • F2G Ltd.
  • Scynexis, Inc.
  • TFF Pharmaceuticals

Strategic Developments

• In October 2022, F2G Ltd announced the IDWeek 2022 positive data from the first 100 patients who completed treatment in its ongoing Phase 2b open-label study of oral olorofim as a treatment for invasive fungal infections. The results state that on days 42 and 84, all-cause mortality (ACM) was 15% and 20%, respectively.

Frequently Asked Questions About This Report

The global chronic pulmonary aspergillosis drugs market is expected to grow at a CAGR of 4.8% in the forecast period.

Pfizer Inc., Merck & Co., Astellas Pharma, Gilead Science Inc., and Novartis AG are a few key players in the global chronic pulmonary aspergillosis drugs market.

The azole antifungals segment dominates the global chronic pulmonary aspergillosis drugs market.

Asia Pacific region is expected to witness the highest global chronic pulmonary aspergillosis drugs market growth in the forecast period.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem 
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL CHRONIC PULMONARY ASPERGILLOSIS DRUGS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
    1. Azole Antifungals
    2. Antibiotics
    3. Others
  6. GLOBAL CHRONIC PULMONARY ASPERGILLOSIS DRUGS MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
    1. Oral
    2. Parenteral
  7. GLOBAL CHRONIC PULMONARY ASPERGILLOSIS DRUGS MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Chronic Pulmonary Aspergillosis Drugs Market
      1. North America Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
      2. North America Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
      3. North America Chronic Pulmonary Aspergillosis Drugs Market, by Country
        1. U.S.
          1. U.S. Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. U.S. Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
        2. Canada
          1. Canada Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. Canada Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
    2. Europe Chronic Pulmonary Aspergillosis Drugs Market
      1. Europe Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
      2. Europe Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
      3. Europe Chronic Pulmonary Aspergillosis Drugs Market, by Country/Region
        1. Germany
          1. Germany Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. Germany Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
        2. U.K.
          1. U.K. Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. U.K. Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
        3. Spain
          1. Spain Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. Spain Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
        4. Italy 
          1. Italy Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. Italy Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
        5. France
          1. France Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. France Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
        6. Rest of Europe 
          1. Rest of Europe Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. Rest of Europe Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
      4. Asia Pacific Chronic Pulmonary Aspergillosis Drugs Market
        1. Asia Pacific Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
        2. Asia Pacific Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
        3. Asia Pacific Chronic Pulmonary Aspergillosis Drugs Market, by Country/Region
          1. China
            1. China Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
            2. China Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
          2. Japan
            1. Japan Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
            2. Japan Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
          3. India
            1. India Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
            2. India Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration 
          4. South Korea
            1. South Korea Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
            2. South Korea Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
          5. Australia
            1. Australia Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
            2. Australia Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
          6. Rest of Asia Pacific 
            1. Rest of Asia Pacific Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
            2. Rest of Asia Pacific Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
      5. Rest of the World Chronic Pulmonary Aspergillosis Drugs Market
        1. Rest of the World Chronic Pulmonary Aspergillosis Drugs Market, By Region
          1. Rest of the World Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
          2. Rest of the World Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
          3. Latin America
            1. Latin America Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
            2. Latin America Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
          4. Middle East & Africa
            1. Middle East & Africa Chronic Pulmonary Aspergillosis Drugs Market, by Drug Class
            2. Middle East & Africa Chronic Pulmonary Aspergillosis Drugs Market, by Route of Administration
  8. COMPANY PROFILES              
    1. Pfizer Inc.
      1. Business Snapshot 
      2.  Ingredient Procedures/Services Offered
      3. Financial Details*
      4. Strategic Developments
    2. Merck & Co.
    3. Astellas Pharma
    4. Gilead Science Inc.
    5. Novartis AG
    6. Johnson & Johnson 
    7. F2G Ltd.
    8. Scynexis, Inc.
    9. TFF Pharmaceuticals

 

*Insights on financial permanence are subject to the availability of information in the public domain


Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Chronic Pulmonary Aspergillosis Drugs Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Chronic Pulmonary Aspergillosis Drugs Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports